Figures & data
Table 1 Demographics and Baseline Characteristics of Our Cohort of 20 Individuals
Figure 2 Flowchart demonstrating the treatments received by individuals with moderate-severe TED and those with DON at baseline, 24 weeks, 52 weeks and 78 weeks.
![Figure 2 Flowchart demonstrating the treatments received by individuals with moderate-severe TED and those with DON at baseline, 24 weeks, 52 weeks and 78 weeks.](/cms/asset/b3ddb0c9-cf5e-47fd-8ddf-fd507de3e9f5/doph_a_12177315_f0002_c.jpg)
Table 2 Ophthalmic Assessments for Individuals with Moderate-Severe TED and Sight-Threatening DON at Baseline, 24 Weeks, 52 Weeks, 78 Weeks
Table 3 Ophthalmic Responses for Individuals with Moderate-Severe TED and Individuals with Sight-Threatening DON at 24 Weeks, 52 Weeks, 78 Weeks vs Baseline
Table 4 Relapses in Those with Moderate-Severe TED and Sight-Threatening DON Occurring by 24 Weeks, 52 Weeks, 78 Weeks
Table 5 Side Effects During Mycophenolate Mofetil Treatment for Our Cohort